MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company’s flagship product for the treatment of HER2+ metastatic breast cancer was approved by the US Food and Drug Administration in December 2020. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite…
ADC Therapeutics. Confronting cancer with the full potential of our science. ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs. ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Visit…
Deciphera Pharmaceuticals Deciphera Pharmaceuticals is focused on discovering, developing, and bringing important new medicines to patients for the treatment of cancer. Enabled by our proprietary kinase switch control inhibitor platform, our drug candidates are designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes…
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the…
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies…
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Coherus is led by a team of biotech industry pioneers focused on disrupting the status-quo and driving tangible change in healthcare. Many of our leaders were directly involved in developing, manufacturing, and commercializing blockbuster biologics that elevated biologics from niche to mainstream medicine. Today, the team is unlocking the true potential of this category and…
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier’s global portfolio…
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and…
Adaptive Biotechnologies Company Description Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the…
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.
For more information about Pharmacyclics LLC, an AbbVie Company, please visit pharmacyclics.com.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products…
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. With our leading-edge processes in manufacturing, strong pipeline of treatments and reliable supply, we strive to improve patient access to more affordable,…
Eisai’s Commitment to Oncology Eisai’s hhc (human health care) mission is to give first thoughts to patients and their families by developing drugs for diseases with significant unmet medical need. Nowhere is this more compelling than in oncology, one of Eisai’s long-standing therapeutic areas of focus since 1987. Eisai continues to grow its commitment to…
Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the…
Biodesix was founded in 2005 to apply the principles of complex data analysis and mass spectrometry (MS) to the discovery and development of improved multivariate tests that give physicians better information to understand the patient and their disease. Understanding the clinically meaningful information contained within each patient’s molecular profile may improve diagnosis and therapeutic intervention…
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative firsts, Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, urology and nephrology. With the same unwavering…
© 2021 FLASCO | Premium Website Design by The HDG
